Overview
Neurofilaments are neuron-specific intermediate filament proteins present in the cytoplasm of neurons in both the central and peripheral nervous systems. They are predominantly located within axons, though they are also found in cell bodies, dendrites, and synapses.
It provides essential structural support to neurons and plays a crucial role in maintaining axonal calibre, which directly affects nerve conduction velocity. They are a major component of the neuronal cytoskeleton and consist of a neurofilament triplet, including light, medium, and heavy subunits. Due to their abundance in axons, these are released into biological fluids when neuronal damage occurs, making them useful indicators of neuroaxonal injury.
Symptoms
Symptoms related to those abnormalities reflect underlying neuronal and axonal damage rather than direct effects of the protein itself. These levels are commonly associated with neurodegenerative and neuroinflammatory conditions. Affected individuals may experience motor weakness, sensory disturbances, and impaired coordination.
Cognitive decline, memory loss, and behavioral changes are frequently observed in conditions such as Alzheimer’s disease. In motor neuron disorders, symptoms may include muscle wasting, fasciculations, and progressive loss of motor function. Following traumatic brain injury, patients may present with headaches, altered consciousness, and focal neurological deficits. The severity of symptoms generally corresponds to the extent of neuroaxonal damage.
Causes
Abnormalities of these levels are caused by damage to neurons and their axons. Neurodegenerative diseases such as amyotrophic lateral sclerosis, multiple sclerosis, and Alzheimer’s disease lead to breakdown of axonal structures, resulting in increased release of neurofilament proteins. In Alzheimer’s disease, reduced gene expression of the light neurofilament subunit contributes to cytoskeletal instability.
Acute neurological insults such as traumatic brain injury also cause axonal disruption and subsequent neurofilament release. Neurofilament expression is observed in tumors of neuronal and neuroendocrine origin, including neuroblastoma, medulloblastoma, retinoblastoma, and pancreatic endocrine tumors, reflecting abnormal neuronal differentiation or damage.
Risk Factors
Risk factors for elevated neurofilament levels include increasing age, as axonal integrity gradually declines over time. A family history of neurodegenerative disorders increases susceptibility to neuroaxonal damage. Chronic neurological conditions involving ongoing inflammation or degeneration significantly raise neurofilament concentrations. Traumatic injuries to the brain or spinal cord further increase risk by causing direct axonal injury.
Certain neural and neuroendocrine tumors contribute to abnormal neurofilament expression. Impaired kidney function may affect neurofilament clearance from circulation, influencing measured levels. Delayed neurological evaluation can result in late detection of conditions associated with neurofilament elevation.
Prevention
Prevention strategies focus on early detection and management of neurological conditions rather than direct prevention of neurofilament release. Early diagnosis of neurodegenerative and inflammatory disorders allows timely intervention to slow disease progression and limit axonal damage. Monitoring these levels, particularly the light chain, supports assessment of disease activity and response to treatment.
Preventing traumatic brain injury through safety measures and prompt medical care reduces acute neuroaxonal injury. Proper collection, handling, and transport of samples are essential to ensure accurate laboratory assessment. Integrating this testing with clinical evaluation and imaging improves early recognition of neuronal damage and supports effective long-term management.
